Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

rafarm, s.a. - ezetimiba - comprimido - 10 mg - ezetimiba 10 mg - ezetimibe - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

rafarm, s.a. - ezetimiba - comprimido - 10 mg - ezetimiba 10 mg - ezetimibe - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

venifar, ltd. - ezetimiba - comprimido - 10 mg - ezetimiba 10 mg - ezetimibe - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

rafarm, s.a. - ezetimiba - comprimido - 10 mg - ezetimiba 10 mg - ezetimibe - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

rafarm, s.a. - ezetimiba - comprimido - 10 mg - ezetimiba 10 mg - ezetimibe - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

rafarm, s.a. - ezetimiba - comprimido - 10 mg - ezetimiba 10 mg - ezetimibe - genérico - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

venifar, ltd. - ezetimiba - comprimido - 10 mg - ezetimiba 10 mg - ezetimibe - genérico - duração do tratamento: longa duração

União Europeia - português - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agentes para dermatite, excluindo corticosteróides - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

União Europeia - português - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - insuficiência cardíaca - a angiotensina ii, os antagonistas, outras combinações, os agentes que actuam no sistema renina-angiotensina - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

União Europeia - português - EMA (European Medicines Agency)

teva b.v. - cloridrato de doxorrubicina - neoplasias do peito - agentes antineoplásicos - myocet lipossomas, em combinação com ciclofosfamida, é indicado para o tratamento de primeira linha de câncer de mama metastático em mulheres adultas.